Market Closed -
Nasdaq
04:00:00 2024-05-24 pm EDT
|
5-day change
|
1st Jan Change
|
27.51
USD
|
-0.94%
|
|
-5.46%
|
-4.94%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,244
|
1,326
|
1,551
|
1,928
|
1,581
|
1,512
|
-
|
-
|
Enterprise Value (EV)
1 |
1,262
|
1,326
|
1,551
|
1,928
|
1,581
|
1,512
|
1,512
|
1,512
|
P/E ratio
|
11.3
x
|
10.7
x
|
29.8
x
|
34.3
x
|
1,447
x
|
110
x
|
-37.2
x
|
35.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
3.17
x
|
2.55
x
|
2.67
x
|
2.89
x
|
2.6
x
|
2.52
x
|
2.42
x
|
2.18
x
|
EV / Revenue
|
3.17
x
|
2.55
x
|
2.67
x
|
2.89
x
|
2.6
x
|
2.52
x
|
2.42
x
|
2.18
x
|
EV / EBITDA
|
-
|
6.91
x
|
13.1
x
|
15
x
|
16.2
x
|
12.9
x
|
12.3
x
|
8.75
x
|
EV / FCF
|
8.86
x
|
9.82
x
|
12.4
x
|
16.6
x
|
-
|
17.3
x
|
14.1
x
|
9.58
x
|
FCF Yield
|
11.3%
|
10.2%
|
8.07%
|
6.04%
|
-
|
5.77%
|
7.1%
|
10.4%
|
Price to Book
|
2.09
x
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
52,463
|
52,685
|
53,181
|
54,058
|
54,633
|
54,974
|
-
|
-
|
Reference price
2 |
23.72
|
25.16
|
29.16
|
35.67
|
28.94
|
27.51
|
27.51
|
27.51
|
Announcement Date
|
2/25/20
|
2/25/21
|
4/13/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
392.8
|
520.4
|
579.8
|
667.2
|
607.5
|
600.1
|
624.6
|
693.5
|
EBITDA
1 |
-
|
191.8
|
118.6
|
128.8
|
97.3
|
117
|
123
|
172.8
|
EBIT
1 |
148.6
|
173.7
|
86.03
|
46.12
|
125.1
|
108.2
|
120.6
|
175.1
|
Operating Margin
|
37.83%
|
33.38%
|
14.84%
|
6.91%
|
20.59%
|
18.03%
|
19.3%
|
25.24%
|
Earnings before Tax (EBT)
1 |
147.5
|
168.6
|
73.18
|
60.74
|
2.769
|
11.64
|
-33.92
|
35.82
|
Net income
1 |
113.1
|
127
|
53.42
|
60.71
|
1.316
|
14.2
|
-41.9
|
44.24
|
Net margin
|
28.79%
|
24.39%
|
9.21%
|
9.1%
|
0.22%
|
2.37%
|
-6.71%
|
6.38%
|
EPS
2 |
2.100
|
2.360
|
0.9800
|
1.040
|
0.0200
|
0.2500
|
-0.7400
|
0.7700
|
Free Cash Flow
1 |
140.4
|
135
|
125.1
|
116.4
|
-
|
87.2
|
107.4
|
157.9
|
FCF margin
|
35.75%
|
25.93%
|
21.57%
|
17.45%
|
-
|
14.53%
|
17.19%
|
22.77%
|
FCF Conversion (EBITDA)
|
-
|
70.35%
|
105.44%
|
90.42%
|
-
|
74.53%
|
87.31%
|
91.4%
|
FCF Conversion (Net income)
|
124.18%
|
106.3%
|
234.13%
|
191.75%
|
-
|
614.08%
|
-
|
356.91%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/25/20
|
2/25/21
|
4/13/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
159
|
152.5
|
170.1
|
177.4
|
167.3
|
153.8
|
135.6
|
153.9
|
164.3
|
143.6
|
148.9
|
153.4
|
154.3
|
149.3
|
155.2
|
EBITDA
1 |
-
|
22.61
|
31.99
|
19.12
|
55.03
|
25.14
|
2.521
|
29.38
|
40.26
|
16.98
|
32.57
|
34.26
|
32.25
|
43.3
|
42.1
|
EBIT
1 |
6.098
|
1.967
|
11.35
|
-1.523
|
34.33
|
30.5
|
10
|
8.138
|
47.1
|
22.3
|
25.38
|
29.36
|
31.12
|
27.1
|
30.65
|
Operating Margin
|
3.83%
|
1.29%
|
6.67%
|
-0.86%
|
20.52%
|
19.84%
|
7.38%
|
5.29%
|
28.66%
|
15.52%
|
17.05%
|
19.14%
|
20.18%
|
18.15%
|
19.75%
|
Earnings before Tax (EBT)
1 |
2.051
|
14.72
|
11.32
|
-0.444
|
35.14
|
9.017
|
-17.13
|
9.889
|
0.99
|
0.243
|
2.381
|
8.376
|
0.641
|
-
|
-
|
Net income
1 |
2.442
|
25.62
|
7.865
|
1.749
|
25.48
|
16.95
|
-0.831
|
-15.98
|
1.175
|
0.124
|
2.94
|
10.34
|
0.792
|
-
|
-
|
Net margin
|
1.54%
|
16.8%
|
4.63%
|
0.99%
|
15.23%
|
11.02%
|
-0.61%
|
-10.38%
|
0.72%
|
0.09%
|
1.98%
|
6.74%
|
0.51%
|
-
|
-
|
EPS
2 |
0.0400
|
0.4300
|
0.1400
|
0.0300
|
0.4300
|
0.2900
|
-0.0200
|
-0.2900
|
0.0200
|
-
|
0.0500
|
0.1800
|
0.0100
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/13/22
|
5/9/22
|
8/4/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/8/23
|
2/27/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
17.3
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
140
|
135
|
125
|
116
|
-
|
87.2
|
107
|
158
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
11.30
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
2.660
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
2.74
|
3.45
|
2.05
|
0.41
|
-
|
4
|
4.25
|
7
|
Capex / Sales
|
0.7%
|
0.66%
|
0.35%
|
0.06%
|
-
|
0.67%
|
0.68%
|
1.01%
|
Announcement Date
|
2/25/20
|
2/25/21
|
4/13/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
27.51
USD Average target price
40.5
USD Spread / Average Target +47.22% Consensus |
1st Jan change
|
Capi.
|
---|
| -4.94% | 1.51B | | +16.41% | 79.16B | | +7.64% | 8.72B | | -16.83% | 4.79B | | +47.36% | 4.62B | | +1.74% | 3.82B | | +14.51% | 2.33B | | -26.23% | 2.2B | | +15.63% | 2.1B | | -34.87% | 2.04B |
Specialty & Advanced Pharmaceuticals
|